Why Dosing Matters More Than the Compound Itself
Most peptide discussions focus on which compounds to use. Far fewer address the question that actually determines outcomes: how much, how often, and for how long. This is a mistake. Two people running the same peptide stack can have entirely different results based solely on their dosing approach, and the gap between an effective dose and one that either undershoots or creates unnecessary side effects is narrower than most beginners expect.
Peptides are signaling molecules. They do not work by accumulation - they work by binding to receptors and triggering downstream biological responses. More is not always better: excessive dosing can downregulate receptor sensitivity, suppress natural production of the hormones being targeted, and introduce side effects that would not occur at therapeutic ranges. Insufficient dosing produces no measurable outcome, which leads users to conclude the compound does not work when the real problem is sub-threshold signaling.
Research indexed on PubMed consistently shows that dose-response relationships for peptide signaling molecules are non-linear: there is a therapeutic window, and operating within it is the entire game. Understanding that window - and how to approach it methodically - is what separates a protocol that delivers results from one that does not.
Core principle: Start at the lower end of the established therapeutic range. Assess your individual response over 2-4 weeks before increasing dose. You can always add; you cannot subtract what you have already injected.
How to Calculate Starting Doses Based on Bodyweight
Many peptide dosing references quote flat mcg amounts without accounting for the single most important variable: the person taking them. A 200-pound person has a meaningfully different volume of distribution than a 130-pound person, which affects both the concentration of the compound at target tissues and its clearance rate.
A widely used convention in peptide dosing practice is to calculate a starting dose on a per-kilogram bodyweight basis, a method borrowed from broader pharmacology. Conservative starting points commonly cited are 1-2 mcg per kilogram of bodyweight per injection. For most peptides in common use, the working ranges are:
- Conservative start: 1-2 mcg per kilogram of bodyweight per injection
- Standard range: 2-4 mcg per kilogram of bodyweight per injection
- Upper range (experienced users): 4-6 mcg per kilogram of bodyweight per injection
For example, a 75kg (165 lb) person starting BPC-157 would begin at 75-150mcg per injection (1-2 mcg/kg), working toward the standard 250-500mcg range only after tolerability and response are confirmed. This is different from how many online sources describe it, but it is the correct pharmacological approach.
Certain compounds - specifically GH secretagogues like CJC-1295, Ipamorelin, and Sermorelin - have more standardized flat dosing in published literature because the receptor saturation curve flattens at relatively low doses and higher doses do not proportionally increase GH output. For these compounds, the flat-dose approach referenced in research is appropriate.
Subcutaneous vs Intramuscular Injection: Which to Use for Which Peptide
Nearly all peptides used in optimization and longevity contexts are administered subcutaneously (subQ) - injected into the fat layer just beneath the skin - rather than intramuscularly (IM). This is not a preference; it is a pharmacokinetic consideration. SubQ injection produces slower absorption into the bloodstream, which maintains compound levels in the therapeutic range for longer and smooths out the peak-and-trough profile.
Subcutaneous (SubQ) - Use For:
- BPC-157: SubQ for systemic effects; local injection into the tissue near an injury for targeted repair. Both approaches are used depending on the goal.
- TB-500: Always subQ. TB-500 works systemically through actin regulation and satellite cell signaling - local injection is unnecessary and offers no advantage.
- CJC-1295 + Ipamorelin: SubQ only. GH secretagogues should never be administered IM; the slower subQ absorption profile better matches the pulsatile nature of GH release.
- Epithalon: SubQ standard; IV is used in some clinic protocols for higher-dose loading.
- Thymosin Alpha-1: SubQ exclusively in published clinical data.
SubQ Injection Technique
- Use an insulin syringe: 28-31G, 1/2 inch needle. The short needle and small bore minimize discomfort and are appropriate for the subQ fat layer.
- Preferred injection sites: abdomen (pinch an inch of fat, 2 inches from the navel), outer thigh, or upper arm fat layer. Rotate sites with each injection to avoid local tissue buildup.
- Insert the needle at a 45-degree angle (or 90 degrees if you have enough fat layer). Inject slowly - over 3-5 seconds. Do not aspirate before injecting subQ (that is only relevant for IM).
- Wipe the injection site with an alcohol swab and let it dry before injecting. Press gently with a clean cotton ball after withdrawing the needle - do not rub.
Intramuscular (IM) - When It Is Used
IM injection is appropriate for BPC-157 when targeting a specific deep muscle injury where subQ injection would not deliver adequate local concentration. Common IM sites for this purpose: the lateral deltoid or vastus lateralis (outer quad). IM requires a longer needle (23-25G, 1 inch minimum) and clean muscle mass at the injection site.
Safety note: Never inject into a vein (IV) outside of a clinical setting with trained medical supervision. SubQ and IM are safe for self-administration when done with proper sterile technique. IV self-administration carries serious infection and air embolism risks.
Reconstituting Peptides with Bacteriostatic Water: Step by Step
Most research-grade peptides are supplied as lyophilized (freeze-dried) powder in a sealed sterile vial. Before injection, they must be reconstituted with bacteriostatic water (BW) - sterile water containing 0.9% benzyl alcohol, which acts as a preservative and allows the reconstituted solution to be stored safely for 4-6 weeks under refrigeration.
Do not use plain sterile water or tap water. Do not use saline unless specifically indicated. Bacteriostatic water is the standard because the preservative prevents bacterial growth in the vial between uses.
| BW Added to 5mg Vial | Concentration | Volume per 250mcg Dose | Volume per 500mcg Dose |
|---|---|---|---|
| 1mL | 5000mcg/mL | 0.05mL (5 units on insulin syringe) | 0.1mL (10 units) |
| 2mL | 2500mcg/mL | 0.1mL (10 units) | 0.2mL (20 units) |
| 2.5mL | 2000mcg/mL | 0.125mL (12.5 units) | 0.25mL (25 units) |
| 5mL | 1000mcg/mL | 0.25mL (25 units) | 0.5mL (50 units) |
Dosing Schedules: Daily, EOD, Pulsed, and Cycling Protocols
The right dosing schedule depends on the compound, the mechanism being targeted, and whether you are in a loading or maintenance phase. There is no universal answer - each compound has pharmacokinetic and pharmacodynamic properties that dictate optimal timing.
Daily Dosing
Used for compounds that benefit from consistent tissue saturation: BPC-157, Thymosin Alpha-1, and GHK-Cu. Daily dosing maintains steady-state compound levels and produces reliable, accumulative effects on the targeted pathways. The dose per injection is relatively low; the benefit comes from consistency over 8-12 weeks rather than any single injection.
Every Other Day (EOD)
A common approach for TB-500 during maintenance phases and for some GH secretagogue protocols where every-day injections would cause receptor desensitization. EOD spacing gives target receptors time to reset between stimulation events, maintaining sensitivity and preventing the diminishing-returns pattern that comes from chronic daily stimulation.
Pulsed Dosing
GH secretagogues (CJC-1295, Ipamorelin, Sermorelin) are almost always dosed in pulses that mimic the body's natural pulsatile GH release pattern. A typical protocol delivers 2-3 injections per day in a fasted state - pre-sleep (most important, aligning with the dominant natural GH pulse), pre-training, and optionally upon waking. This pulse approach produces meaningfully higher peak GH output than a single large daily dose and avoids the baseline suppression that continuous stimulation causes.
Cycling
Most peptide protocols run 8-12 weeks on followed by a 4-week off period. The off period allows receptor sensitivity to reset, pituitary feedback loops to normalize, and natural production pathways to recover. Continuous use without cycling progressively blunts the response as the body adapts to persistent receptor stimulation. The one exception is BPC-157, which some practitioners use continuously at maintenance doses given its excellent tolerability profile and non-hormonal mechanism.
BPC-157 Dosing: Systemic vs Local
BPC-157 (Body Protective Compound-157) is a synthetic 15-amino-acid peptide derived from a protective protein found in gastric juice. It is among the most widely studied peptides in both injury repair and systemic anti-inflammatory contexts, with dozens of animal studies and a growing body of human clinical interest indexed on PubMed.
Dose Range
The established therapeutic range from the research literature is 250-500mcg per injection. Most users start at 250mcg twice daily (morning and evening) and assess tolerability and response before moving to 500mcg. Some practitioners use 500mcg twice daily for the first 2-4 weeks as a loading phase, then reduce to once-daily maintenance.
Systemic Use
For general anti-inflammatory support, gut health, and recovery optimization, BPC-157 is injected subcutaneously in the abdomen or thigh. The compound is absorbed into circulation and distributes systemically, working through its anti-inflammatory and angiogenic mechanisms throughout the body. This approach is appropriate for general use cases rather than specific localized injuries.
Local Use (Near-Injury Injection)
For specific musculoskeletal injuries - tendon tears, ligament damage, joint inflammation - BPC-157 can be injected subcutaneously or intramuscularly at the site of injury or in the tissue immediately adjacent to it. The local concentration enhances the angiogenic and repair-signaling effects at the specific injury site. Both approaches (systemic and local) can be used simultaneously: systemic subQ for overall recovery environment, local injection for targeted tissue repair.
Cycle Length
For injury-specific use: 4-8 weeks, then reassess. For general systemic use: 8-12 weeks on, 4 weeks off. Some practitioners run BPC-157 on a longer low-dose cycle (250mcg/day) given its tolerability and relatively benign mechanism compared to hormone-modulating peptides.
TB-500 Dosing: Loading and Maintenance
TB-500 (Thymosin Beta-4) is a naturally occurring peptide found in virtually all human and animal cells. It operates systemically through actin regulation, modulating cell migration, differentiation, and survival - making it particularly effective for systemic recovery, inflammation reduction, and healing of damage across multiple tissue types simultaneously.
Loading Phase (Weeks 1-4 to 6)
The established loading protocol is 2-2.5mg twice weekly (for example, Monday and Thursday). This loading phase builds up sufficient compound in the tissue to produce measurable effects on recovery and inflammation. Many users report noticing improved recovery speed and reduced joint soreness within the first 2 weeks of loading.
Maintenance Phase (After Loading)
Once loading is complete, shift to 2-2.5mg once weekly. This maintenance dose sustains the tissue-level Thymosin Beta-4 concentration established during loading without the need for continued twice-weekly injections. Maintenance can continue for the duration of the cycle (typically 8-12 weeks total from the start of loading).
Injection Route and Timing
SubQ injection only. TB-500 works systemically - local injection near injuries is not necessary and the compound distributes effectively from any subQ injection site. Timing is flexible; TB-500 does not have the fasted-state requirement of GH secretagogues and can be injected with or without food.
Stacking with BPC-157
The BPC-157 + TB-500 combination is the most commonly used peptide stack for recovery and tissue repair, and for good reason: the two compounds work through complementary mechanisms. BPC-157 drives local angiogenesis and inflammation resolution; TB-500 works systemically through actin regulation and satellite cell recruitment. Run together, they create a tissue environment that accelerates recovery from training stress and injury simultaneously.
CJC-1295 + Ipamorelin Dosing: The GH Stack
CJC-1295 (a modified GHRH analogue) and Ipamorelin (a ghrelin receptor agonist) are almost always run together because they work through different but synergistic receptor pathways to produce a larger, cleaner GH pulse than either compound produces alone. CJC-1295 extends the duration and amplitude of the pituitary GH pulse; Ipamorelin adds a clean, selective GH release signal without the cortisol or prolactin elevation associated with older secretagogues like GHRP-2 or GHRP-6.
Dose per Injection
The standard dose is 100mcg of each compound (CJC-1295 and Ipamorelin) per injection. This is notably lower than many online protocols suggest. Published research on GHRP receptor saturation shows that doses above approximately 100mcg per compound produce minimal additional GH output while increasing the likelihood of side effects (water retention, tingling, GH-related fatigue at higher doses). More is not more with this stack.
Injection Frequency and Timing
Inject 2-3 times daily in a fasted state, with the pre-sleep dose being the most important (aligning with the dominant natural GH pulse during slow-wave sleep). A practical protocol:
- Pre-sleep: 100mcg CJC-1295 + 100mcg Ipamorelin, 30-60 minutes before bed on an empty stomach (at least 2 hours after the last meal)
- Pre-training (optional): 100mcg each, 30 minutes before training in a fasted state
- Upon waking (optional, 3x/day protocols): 100mcg each, immediately upon waking before any food or drink
The fasted state requirement is non-negotiable: insulin (elevated after eating) directly suppresses GH pulse amplitude. Injecting these compounds in a fed state substantially reduces the GH response.
Cycle Structure
12-16 weeks on, 4-6 weeks off. Monitor IGF-1 levels at weeks 6-8 and at the end of the cycle. IGF-1 is the downstream marker of GH output and the most practical way to confirm the stack is producing the intended effect at your dose.
Common Beginner Mistakes and How to Avoid Them
Most failed peptide protocols are not caused by bad compounds - they are caused by correctable errors in dosing and administration. These are the mistakes that appear most consistently:
Starting Too High
The instinct to start at the top of the dose range to "see results faster" is almost always counterproductive. Starting high means you have no room to titrate up if needed, you cannot distinguish side effects from therapeutic response, and you risk desensitizing receptors before establishing your baseline. Start at the lower third of the established range. Add dose only if response is insufficient after 2-4 weeks.
Injecting in a Fed State (GH Secretagogues)
CJC-1295 and Ipamorelin are frequently underdosed by being injected right after eating. The insulin spike from a meal suppresses the GH pulse these compounds are trying to produce. A 2-3 hour fast before injection is the minimum; the pre-sleep injection (where 8+ hours of fasting follows) is the most effective window for this reason.
Using Plain Sterile Water Instead of Bacteriostatic Water
Plain sterile water contains no preservative. A reconstituted vial is opened and closed repeatedly over 4-6 weeks - bacteriostatic water's benzyl alcohol is what keeps the solution free of bacterial contamination during that period. Using plain water creates infection risk with every injection. Use bacteriostatic water.
Not Rotating Injection Sites
Injecting the same site repeatedly creates local tissue thickening (lipohypertrophy) that impairs absorption and becomes visible over time. Maintain a rotation map: abdomen (4 quadrants), outer thighs, and upper arms give you a large enough rotation to avoid any single site more than once per week.
Shaking the Vial
Peptides are fragile molecules. Shaking the reconstituted vial introduces mechanical stress and air bubbles that can denature (deactivate) the compound. Always swirl gently. If you see persistent cloudiness after swirling, the peptide may be damaged or the reconstitution water was incorrect.
No Cycle Structure
Running GH secretagogues continuously without a break is one of the most common mistakes in longer-term users. After 12-16 weeks of continuous CJC-1295/Ipamorelin use, GH pulse amplitude typically declines as pituitary sensitivity adapts downward. The 4-6 week off period is not dead time - it is when pituitary sensitivity resets and the next cycle becomes effective again.
No Biomarker Tracking
Running a peptide protocol without any objective measurement is operating on feel. IGF-1 (for GH axis compounds), hs-CRP (for anti-inflammatory peptides), and body composition (for muscle-focused stacks) give you the data to know whether your dosing is working and when to adjust. No bloodwork means no signal - only noise.
How to Track Your Doses and Responses Over Time
The information that makes a peptide protocol improvable over time is not stored in your memory - it is in the pattern of your injection log compared against your biomarker data and subjective response scores. Most people who run multiple cycles without progressing are missing this tracking layer.
Effective peptide tracking captures four dimensions:
- Injection log: Date, compound, dose, site, and time of day for every injection. This creates the audit trail that lets you correlate specific dosing decisions with outcomes.
- Response metrics: Recovery speed (soreness 24-48 hours after training), sleep quality (time to sleep, depth, morning readiness), energy, and mood. These are the early-response signals that tell you whether a compound is working at your dose.
- Bloodwork at baseline, mid-cycle, and end of cycle: IGF-1, hs-CRP, and any other markers relevant to your specific stack. Bloodwork is expensive if you do it wrong - targeted, timed labs are far more informative than broad panels run at the wrong time in the cycle.
- Body composition at baseline and end of cycle: Weight alone is not enough. DEXA or a reliable BodPod gives you lean mass and fat mass separately, which is the only way to know whether a performance stack is actually shifting your composition rather than just your weight.
BioStackIQ is built specifically for this tracking layer. The protocol builder lets you add each compound in your stack, set your dosing schedule and cycle dates, log injections directly from the dashboard, and record biomarker results alongside your protocol timeline. When you pull your IGF-1 results at week 12, you can see exactly what you were running, at what dose, and on which days - the context that makes the number meaningful rather than just a data point in isolation. Build your tracking protocol at biostackiq.com - setup takes under five minutes.
Conclusion: Dose Right, Track Everything, Adjust Based on Data
Peptides work. The question is whether your protocol is designed to let them. The compounds are only one variable in a multi-variable system - and dosing, timing, injection technique, reconstitution, cycling structure, and tracking are the variables you actually control. Getting those right is what separates a protocol that delivers measurable results from one that does not.
Start conservatively. Confirm tolerability before adding dose. Use bacteriostatic water and proper sterile technique. Respect the fasted-state requirement for GH secretagogues. Cycle off before receptor sensitivity declines. And track everything - injections, response scores, and bloodwork - so each cycle is more informed than the last.
The biohackers who compound the most results over time are not the ones with the most aggressive protocols. They are the ones who run methodical protocols, measure the outcomes, and use that data to improve the next cycle.